Chilean scientists discover how a new form of heart failure is emerging


At present, the coexistence of several cardiovascular risk factors – obesity, diabetes mellitus, high cholesterol, sedentary lifestyle, smoking and high blood pressure, which is characteristic of today's society, has led to the emergence of a new cardiovascular pathology known as Heart failure with preserved systolic function.

This new form of deprivation prevents proper heart release, as it affects almost half of patients with heart failure, both in Chile and in countries with higher levels of development.

So far, the mechanisms that they have created and the effective therapy for the treatment of this pathology have not been known. But Research conducted by scientists from the University of Chile and the Advanced Center for Chronic Disease Control (ACCDiS), along with researchers at the Southwestern Medical Center of the University of Texas, USA, revealed how this disease occurs. after imitating it in an animal model that faithfully imitates what is happening in a human being, a finding that opens the door for the development of healing.

The work of Nature, the most important scientific journal on the planet, in an article published in the journal Nature, titled "Nitrosal stress drives cardiac failure with a preserved ejection fraction" – describes that an increase in nitric oxide causes damage to the heart by altering the action of two proteins, responsible for the protection of the heart: IRE1α and XBP1s.


Heart failure is the final stage of several cardiovascular diseases, which are very common in our population, including hypertension and myocardial infarction.

Experts estimate this pathology as Emerging epidemicdue to the increasing prevalence and high costs demanded by healthcare systems that affect more than 26 million people worldwide and are the leading cause of death globally and in Chile (30% of deaths in the country).

The team that makes up cardiologists Gabriele Schiattarella, Joseph A. Hill and Chileans Francisco Altamirano, Elisa Villalobos and Sergio Lavandero, who has been working on this new pathology and how to deal with it for more than seven years.

For Francisco Altamirano, this finding is "A tremendous achievement that will enable future therapies for this new pathology".

Sergio Lavandero Director of ACCDiS, professor at the Faculty of Chemistry and Pharmaceutical Sciences and Medicine at the University of Chile and author of this study, stressed that "this new form of heart failure is a strategic issue for ACCDiS, because we need to be fully in line with current and future challenges cardiovascular system. "

He also emphasized that the most important scientific journal in the world published this publication, including commenting on the supplementary note, because this discovery is of great importance. In addition, he emphasized the importance of cooperation between universities in the country and the support of the Center of Excellence Program in the priority areas of the Fondap of Conicyt. Lavandero finally revealed the need to continue investing in science in order for the country to achieve a new level of development.

Gabriele Schiattarella He emphasized the fundamental role of Chilean scientists in this project. "Altamirano contributed to deep biochemical knowledge, Villalobos carried out fundamental experiments, and Lavandero led me in the design and implementation of these studies. To summarize, this publication in Nature could not have happened without the contribution of this group of Chilean scientists, "he said.


Source link